Target LncRNA CYTOR reverse enzalutamide resistance in castration resistant prostate cancer through regulating alternative splicing of AR-V7

Target LncRNA CYTOR reverse enzalutamide resistance in castration resistant prostate cancer through regulating alternative splicing of AR-V7

Bibliographic Details
Main Authors:	Z. Shang, Y. Niu, J. Yu
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320338349

Similar Items

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
by: Zeyuan Zheng, et al.
Published: (2022-10-01)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
by: Boya Zhang, et al.
Published: (2021-09-01)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015-06-01)

Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation
by: Iris Simon, et al.
Published: (2021-03-01)

A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer
by: Peng Gu, et al.
Published: (2019-06-01)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-08-01)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
by: Joelle El-Amm, et al.
Published: (2013-01-01)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
by: Keliang Wang, et al.
Published: (2020-06-01)

Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
by: Qiuhui Li, et al.
Published: (2018-09-01)

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer
by: Greasley R, et al.
Published: (2015-06-01)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
by: Joelle El-Amm, et al.
Published: (2013-01-01)

Erratum for “Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide”
by: Joelle El-Amm, et al.
Published: (2013-11-01)

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer
by: Khrystany T. Isebia, et al.
Published: (2023-03-01)

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
by: Mayao Luo, et al.
Published: (2022-11-01)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
by: Benjamin L Maughan, et al.
Published: (2014-12-01)

CYTOR drives prostate cancer progression via facilitating AR‐V7 generation and its oncogenic signalling
by: Jianpeng Yu, et al.
Published: (2023-05-01)

Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7
by: Haojie Chen, et al.
Published: (2022-05-01)

Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
by: Zhongbo Du, et al.
Published: (2021-03-01)

Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer
by: Stefanie Fischer, et al.
Published: (2020-01-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
by: Mona Kafka, et al.
Published: (2020-07-01)

KEYNOTE-641 phase 3 study of pembrolizumab plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer
by: A. Stenzl, et al.
Published: (2020-07-01)

Identification of key enzalutamide-resistance-related genes in castration-resistant prostate cancer and verification of RAD51 functions
by: Xu Wen, et al.
Published: (2023-05-01)

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer
by: Xi Chen, et al.
Published: (2022-07-01)

Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide
by: A. H. Zedan, et al.
Published: (2023-10-01)

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
by: Michael T Schweizer, et al.
Published: (2018-01-01)

Influence of treatment with abiraterone and enzalutamide on development of sarcopenia in patients with metastatic castration resistant prostate cancer
by: S. Fischer, et al.
Published: (2020-07-01)

Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer
by: Ayşe Demirci, et al.
Published: (2021-07-01)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
by: Luo J, et al.
Published: (2016-11-01)

Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer
by: Debanjan Saha, et al.
Published: (2024-02-01)

The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide
by: So Nakamura, et al.
Published: (2024-02-01)

344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
by: Arnulf Stenzl, et al.
Published: (2020-11-01)

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT)
by: Jae Duck Choi, et al.
Published: (2021-11-01)

Enzalutamide-Resistant Progression of Castration-Resistant Prostate Cancer Is Driven via the JAK2/STAT1-Dependent Pathway
by: Yong Luo, et al.
Published: (2021-10-01)

ENO2 Promotes Colorectal Cancer Metastasis by Interacting with the LncRNA CYTOR and Activating YAP1-Induced EMT
by: Chunwei Lv, et al.
Published: (2022-08-01)

lncRNA cytoskeleton regulator RNA (CYTOR): Diverse functions in metabolism, inflammation and tumorigenesis, and potential applications in precision oncology
by: Chunlin Ou, et al.
Published: (2023-03-01)

Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide
by: Phoebe A. Tsao, et al.
Published: (2023-08-01)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
by: Carlo Cattrini, et al.
Published: (2022-03-01)

High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients
by: Yu-Ting Hsieh, et al.
Published: (2021-08-01)

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
by: Shunsuke Tsuzuki, et al.
Published: (2021-01-01)